Kevin Alexander retweeted
Milestone reached!🫀
Today, @StVincentIN celebrated our 500th HeartMate 3 LVAD implant—500 lives transformed and 500 families given renewed hope.
Grateful for our entire incredible MCS team and resilient patients!
It takes a village!
@shwinner @KayMorrisMong @AnotherAPatelMD
Kevin Alexander retweeted
Proud to share our newly published study in the Journal of Echocardiography!
In CA, MCF ≤25% was independently associated with higher mortality (adjusted HR 5.46; p=0.006).
Promising findings that warrant further validation.
🔗 doi.org/10.1007/s12574-026-0…
Kevin Alexander retweeted
Looking forward to being part of this at HFSA
🫀 ATTR-CM can be overlooked or diagnosed late. Learn to recognize common clinical scenarios, apply evidence-based treatment across disease stages, and explore emerging therapies. 🔬 #HFSA2026
👉 Save your spot: mdsc.pe/4xZqxAn
Kevin Alexander retweeted
#Myeloma Paper of the Day: Transcriptome analysis of AL #amyloidosis pt myocardial samples finds upregulation of fibroblast activation genes (e.g. collagen type I/III & periostin), fibroblast-to-myofibroblast transition in vitro & matrix remodeling: pubmed.ncbi.nlm.nih.gov/4280…. #alsm
Kevin Alexander retweeted
Now published in Heart Failure Reviews:
Atrial fibrillation in ATTR-CM: marker of disease severity and implications for multidomain reassessment.
Grateful to my co-authors for their collaboration and especially to Kevin M. Alexander, MD, for his guidance and valuable insights throughout this work.
🔗 rdcu.be/18UJsY5V1nVa
#ATTRCM #CardiacAmyloidosis #AtrialFibrillation
Kevin Alexander retweeted
Observation in amyloidosis: Daratumumab can kill active plasma cells. Question: Can it help in pre-🫀 transplant desensitization? Answer: Yes! Excited to publish this study (a true labor of love!) in @JCardFail. onlinejcf.com/article/S1071-…
Kevin Alexander retweeted
Replying to @DorbalaSharmila
@DorbalaSharmila presented the results of the #REVEAL study - Evuzamitide PET/CT in cardiac amyloidosis
Amazing results of this first ever rigorously conducted multicenter trial of an imaging agent in cardiac amyloidosis
We are so thankful for the commitment of patients and investigators to the conduct of this investigator initiated trial.
Simultaneously published in @JAMA_current
jamanetwork.com/journals/jam…
#cardiotwitter
#ESC2026
#ESCCongress
#ESCCongress2026
#ESCCongressMedIQ
Kevin Alexander retweeted
Paper out: "Persistent Primary Graft Dysfunction Stratifies Risk After Heart Transplantation w/Lower Mortality Among Recipients of Donation-After-Circulatory-Death Hearts” by Alexander Berg, @JW_MacArthur, et al✨ @aravindkrishnan @ElbertHeng @AliceLiZhou ow.ly/Vpij50ZBBhy
Kevin Alexander retweeted
The p.Val142Ile (Val122Ile) variant is the most common hereditary ATTR amyloidosis mutation in the U.S., disproportionately affecting individuals of African ancestry. This review highlights ongoing challenges in timely diagnosis, genetic screening, access to specialty care, and equitable treatment, while outlining priorities to improve outcomes through earlier identification, multidisciplinary care, and more inclusive clinical trials. A timely and important read (link.springer.com/article/10…) #HREV @senthil_selv @KMAlexanderMD @NotNoninvasive
Kevin Alexander retweeted
In ATTR-CM, atrial fibrillation is present in the majority of patients. The ATTRibute-CM trial showed that 69% of participants had AF at baseline, and many went on to experience new or worsening AF events during follow-up.
With patients living longer, the clinical burden of arrhythmias is becoming a central part of ATTR-CM management. AF is not only common but is associated with more advanced disease, higher NT-proBNP, worse functional status, and increased hospitalizations.
Our post-hoc analysis published in @JCardFail found that acoramidis reduced the frequency of recurrent new or worsening AF events by 26% versus placebo over 30 months, independent of baseline AF. There was also a numerical reduction in adjudicated AF-related cardiovascular hospitalizations with acoramidis.
These data add to the growing evidence that disease-modifying therapy can favorably impact multiple aspects of ATTR-CM beyond the primary heart failure endpoints.
onlinejcf.com/article/S1071-…
Missed our live #ATTR symposium at #HRS2026 with Drs. Kevin M. Alexander & Eoin Donnellan? Watch the event and download free clinical resources for the EP lab here: bit.ly/4pIJgwK @KMAlexanderMD #MedEd #EPeeps #cardiology
With awareness of #ATTR growing, what do electrophysiologists need know about its cardiac manifestation & related conditions like atrial fibrillation? Watch this MasterClass w/ Drs Kevin M Alexander & Eoin Donnellan to learn: bit.ly/4pIJgwK #HRS2026 @KMAlexanderMD
Huge thanks to @EoinDonnellan1 & @KMAlexanderMD for an insightful discussion at #HRS2026! Key clinical insights, practical applications, and real-world relevance throughout.
📺 Watch the replay: bit.ly/26ATTR-CA-T
With appreciation to @BridgeBioPharma for grant support! #CME #MedEd
Kevin Alexander retweeted
Excellent @PeerView session today on Electrophysiologic Insights into ATTR-CM with @KMAlexanderMD & Dr. Eoin Donnellan.
Asked about AF as a marker of advanced disease vs independent driver of mortality — same signal we observed in our Cuban ATTR-CM cohort:
🫀 AF tracked disease severity
🫀 Lost significance after multivariable adjustment
#CardioAmyloidosis #CardioTwitter #ATTRCM
Kevin Alexander retweeted
Awesome session. Thanks to @PeerView and @KMAlexanderMD.
Watch Drs. Kevin M. Alexander (@KMAlexanderMD) & Eoin Donnellan (@EoinDonnellan1) discuss the latest #ATTR updates during #HRS2026 – to participate, visit: bit.ly/26ATTR-CA-T nitter.cf/i/broadcasts/1nGeLyYZO…
🌟 Join PeerView Live at McCormick Place Convention Center (Room S103)—or virtually—during #HRS2026! Starting at 11:30AM CDT, hear from @KMAlexanderMD & @EoinDonnellan1 on managing atrial fibrillation in transthyretin cardiac #amyloidosis. Register: bit.ly/26ATTR-CA-T
#MedEd
Kevin Alexander retweeted
🫀 ATTR-CA. Don’t miss it. Don’t miss THIS.
⚡ Live EP insights. Real-world strategies. Immediate impact.
Join @PeerView at #HRS2026
with @KMAlexanderMD & Eoin Donnellan, MD
📅 4/23 | ⏰ 11 AM CDT
🎯 Show up. Level up
Seeing you 🫵 there‼️
Register 👉 bit.ly/26ATTR-CA-T
Expand your treatment toolbox for managing atrial fibrillation in patients with transthyretin cardiac #amyloidosis with @KMAlexanderMD ➡️ 4/23 at 11:00 AM CDT: bit.ly/26ATTR-CA-T #HRS2026 #EPeeps #cardiology #MedEd
Kevin Alexander retweeted
Editorial comment by @KMAlexanderMD and I on how can focus on the root causes of these trends with strategies to consider for HF prevention, ambulatory care, enterprise level approaches in managing patients with chronic HF @JACCJournals
🔗 jacc.org/doi/10.1016/j.jchf.…
Join Kevin M. Alexander, MD, FACC, FHFSA (@KMAlexanderMD), & Eoin Donnellan, MD, on 4/23 at 11:00 AM CDT during #HRS2026 for an #ATTR #MedEd event ➡️ bit.ly/26ATTR-CA-T #EPeeps #cardiology #amyloidosis #MedEd









































